Clinical Trial

Clonal Hematopoiesis in Giant Cell Arteritis

Study acronym: CH-GCA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to verify whether CHIP is correlated with the clinical, instrumental, and histological characteristics of GCA, and to characterize the pathogenetic effects of clonal hemopoiesis on vasculitis. The main objective of this study is to verify if clonal hematopoiesis of indeterminate potential (CHIP) affects GCA manifestations, course/response to therapies, and pathogenesis. Patients who are going to be diagnosed with GCA and for which a fast track is available for a rapid diagnostic work-up including pre-treatment temporal artery biopsy. Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. The presence and characteristics of CHIP will be correlated with baseline clinical, instrumental, and histologic GCA features.
Trial Details
NCT Number NCT06244069
Lead Sponsor ASST Fatebenefratelli Sacco
Conditions Giant Cell Arteritis, Temporal Arteritis, Clonal Hematopoiesis of Indeterminate Potential, Horton Disease, Systemic Vasculitis Primary
Enrollment 326 participants
Start Date 2024-03
Primary Completion 2028-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2024-02-06